Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds [5]

International Journal of Antimicrobial Agents

Volumn 25, Issue 4, 2005, Pages 352-353

  Gracia, Matilde ^a   Ponte, Carmen ^a   Soriano, Francisco ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLAVULANIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); DILUTION; ESCHERICHIA COLI; INOCULATION; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 15244354725     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.01.008     Document Type: Letter

References (8)

1. R. Reynolds, N. Potz, M. Colman, A. Williams, D. Livermore, and A. MacGowan Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC bacteraemia resistance surveillance programme J Antimicrob Chemother 53 2004 1018 1032
2. X. Bertrand, and D. Talon In vitro activity of co-amoxiclav acid against clinical isolates of Escherichia coli J Antimicrob Chemother 47 2001 719 730
3. C. Henquell, D. Sirot, and C. Chanal Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France J Antimicrob Chemother 34 1994 707 714
4. E. Miro, F. Navarro, and B. Mirelis Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period Antimicrob Agents Chemother 46 2002 3991 3994
5. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 5th ed. Approved standard M7-A5. Wayne, PA: NCCLS; 2000.
6. O. Burkhardt, K. Borner, and N. von der Höh Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy volunteers J Antimicrob Chemother 50 2002 707 712
7. C.M. Kaye, A. Allen, and S. Perry The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate Clin Ther 23 2001 578 584
8. J. Finlay, L. Miller, and J.A. Poupard A review of the antimicrobial activity of clavulanate J Antimicrob Chemother 52 2003 18 23